BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA lowered its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 3.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,229,287 shares of the biotechnology company’s stock after selling 542,886 shares during the quarter. Primecap Management Co. CA owned approximately 7.93% of BioMarin Pharmaceutical worth $824,818,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in BMRN. Quent Capital LLC acquired a new stake in shares of BioMarin Pharmaceutical in the third quarter worth approximately $28,000. Smartleaf Asset Management LLC raised its stake in BioMarin Pharmaceutical by 92.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 360 shares during the last quarter. Hantz Financial Services Inc. lifted its holdings in BioMarin Pharmaceutical by 480.2% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 874 shares in the last quarter. Employees Retirement System of Texas acquired a new stake in BioMarin Pharmaceutical during the 2nd quarter worth $58,000. Finally, Jones Financial Companies Lllp boosted its stake in BioMarin Pharmaceutical by 88.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,401 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 656 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Sanford C. Bernstein increased their target price on shares of BioMarin Pharmaceutical from $90.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday. Truist Financial upped their price objective on shares of BioMarin Pharmaceutical from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. Oppenheimer cut their price objective on shares of BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a report on Tuesday. Piper Sandler decreased their target price on shares of BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Finally, Tudor Pickering set a $88.00 price target on BioMarin Pharmaceutical in a research report on Monday, November 3rd. Fifteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.43.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $61.44 on Thursday. The company has a current ratio of 5.21, a quick ratio of 3.10 and a debt-to-equity ratio of 0.10. The company has a 50-day moving average price of $58.72 and a 200 day moving average price of $56.12. BioMarin Pharmaceutical Inc. has a 12-month low of $50.76 and a 12-month high of $73.51. The stock has a market cap of $11.80 billion, a P/E ratio of 34.52, a PEG ratio of 0.68 and a beta of 0.26.

Key Stories Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q4 earnings beat and record/strong revenue growth driven by Voxzogo, which supports near-term fundamentals. Q4 Highlights
• Positive Sentiment: Sanford C. Bernstein raised its price target to $94 and keeps an “outperform” rating, signaling bullish conviction from a major shop. Bernstein PT Raise
• Positive Sentiment: TD Cowen/Phil Nadeau maintained a Buy rating with a $120 price target, highlighting confidence in multi‑year growth and recent strategic moves. TD Cowen Note
• Neutral Sentiment: Bank of America reiterated a Buy but trimmed its target to $97, reflecting confidence in long-term upside while acknowledging nearer-term pressures. BofA Note
• Neutral Sentiment: Management will present at four investor conferences in March, which could provide additional investor visibility and updates on pipeline strategy. Investor Conferences
• Neutral Sentiment: Public short-interest data for February is effectively zero/unclear (likely reporting artifact) and does not appear to be a driver of today’s move.
• Negative Sentiment: BioMarin said it will voluntarily withdraw Roctavian (its hemophilia gene therapy) from the market — a material strategic setback that raises questions about near- and medium-term revenue trajectory and risk profile. Roctavian Withdrawal
• Negative Sentiment: Several analysts trimmed targets or issued more cautious notes (Guggenheim lowered to $86, HC Wainwright cut to $55 and moved to Neutral), creating mixed sell-side signals and short-term pressure. Analyst Revisions

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.